Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Anne-Charlotte Teyssier"'
Autor:
Anne-Charlotte Teyssier, Gérard Michel, Charlotte Jubert, Fanny Rialland, Sandrine Visentin, Marie Ouachée, Karin Bilger, Virginie Gandemer, Yves Beguin, Aude Marie-Cardine, Yves Chalandon, Marc Ansari, Karine Baumstarck, Anderson Loundou, Jean-Hugues Dalle, Anne Sirvent
Publikováno v:
Transplantation and Cellular Therapy
Transplantation and Cellular Therapy, 2022, 28 (11), pp.780.e1-780.e7. ⟨10.1016/j.jtct.2022.08.019⟩
Transplantation and Cellular Therapy, 2022, 28 (11), pp.780.e1-780.e7. ⟨10.1016/j.jtct.2022.08.019⟩
International audience; We previously reported results of a French randomized clinical trial (RCT) comparing the risk of transplantation failure (including transplant-related mortality [TRM], engraftment failure, and autologous recovery) in single an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47d6d11c32fe9e889fd33b57cd26b396
https://doi.org/10.1016/j.jtct.2022.08.019
https://doi.org/10.1016/j.jtct.2022.08.019
Autor:
Franciane Paul, Isabelle Diaz, Sylvain Lamure, Safia Belbachir, Alexandre Theron, Pierre Rocanieres, Eve Gehlkopf, Guillaume Cartron, Aguilar-Martinez Patricia, Elena Properzi, Anne-Charlotte Teyssier, Charles Herbaux, Patrice Ceballos, Emmanuelle Tchernonog, Nathalie Fegueux, Jean-Jacques Tudesq
Publikováno v:
Blood. 138:4839-4839
Background. Immunotherapy with chimeric antigen receptor T (CAR-T cells) is a new therapeutic approach approved for patients with relapsed/refractory (R/R) B-lymphoproliferative malignancies. Specific toxicities have been described following CAR-T ce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4ea267136c8bcae7c19f8f838a4972df
https://doi.org/10.1182/blood-2021-152465
https://doi.org/10.1182/blood-2021-152465
Autor:
Arnaud Petit, Anne-Charlotte Teyssier, Stéphane Ducassou, Guy Leverger, Odile Fenneteau, André Baruchel, Wendy Cuccuini, Paola Ballerini, Christine Ragu, Marlène Pasquet, Claude Preudhomme, Nicolas Sirvent, Hélène Lapillonne, Thomas Mercher
Publikováno v:
Pediatric Hematology-Oncology
Pediatric Hematology-Oncology, Taylor & Francis, 2017, 34 (8), pp.425--427. ⟨10.1080/08880018.2017.1414905⟩
Pediatric Hematology-Oncology, 2017, 34 (8), pp.425--427. ⟨10.1080/08880018.2017.1414905⟩
Pediatric Hematology-Oncology, Taylor & Francis, 2017, 34 (8), pp.425--427. ⟨10.1080/08880018.2017.1414905⟩
Pediatric Hematology-Oncology, 2017, 34 (8), pp.425--427. ⟨10.1080/08880018.2017.1414905⟩
International audience; We report the outcome of 27 children with de novo acute megakaryoblastic leukemia (AMKL) (excluding Down syndrome) enrolled in the French multicenter prospective study ELAM02 (2005-2011). There was no difference in gender, ini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d3af96d310c238d3c83613a85c3da03
https://pubmed.ncbi.nlm.nih.gov/29303660
https://pubmed.ncbi.nlm.nih.gov/29303660